Giuliano A E, Feig S, Eilber F R
Cancer. 1984 Nov 15;54(10):2160-4. doi: 10.1002/1097-0142(19841115)54:10<2160::aid-cncr2820541016>3.0.co;2-p.
The clinical courses of 111 patients with osteosarcoma treated at UCLA between 1971 and 1982 were reviewed to ascertain the evolution of the natural history of this disease. Only patients with classic high-grade intraosseous osteosarcoma of the extremity, scapula, or pelvis were considered. Patients with low-grade parosteal osteosarcomas; primary osteosarcomas of the face, skull, vertebra, or ribs; and osteosarcomas arising in Paget's disease or previously irradiated bones were not included. Fifty-nine patients developed clinically evident distant metastases. Of these, 36 developed pulmonary metastases alone as the initial site of recurrence. Eighteen of 19 (94.7%) patients treated between 1971 and 1974 by amputation alone developed pulmonary relapse as the initial site of recurrence, whereas only 18 of 40 patients (45%) treated after 1974 with surgery and adjuvant chemotherapy developed pulmonary metastases alone as the initial site of recurrence. Although no patients in the early group developed an extrapulmonary metastasis as the initial site of recurrence, 11 of 40 patients (27.5%) treated with adjuvant chemotherapy developed an extrapulmonary metastasis as the initial site of recurrent disease, and 11 patients developed simultaneous pulmonary and extrapulmonary metastases. Although it is impossible to attribute this alteration in metastatic pattern to adjuvant chemotherapy alone, it is apparent that nonpulmonary metastases are becoming more common among patients currently treated for osteosarcoma.
回顾了1971年至1982年间在加州大学洛杉矶分校接受治疗的111例骨肉瘤患者的临床病程,以确定这种疾病自然史的演变。仅纳入了患有四肢、肩胛骨或骨盆经典高级别骨内骨肉瘤的患者。低级别骨旁骨肉瘤患者;面部、颅骨、椎骨或肋骨的原发性骨肉瘤患者;以及佩吉特病或先前接受过放疗的骨骼中发生的骨肉瘤患者均未纳入。59例患者出现了临床明显的远处转移。其中,36例仅发生肺转移作为复发的初始部位。1971年至1974年间仅接受截肢治疗的19例患者中有18例(94.7%)以肺复发作为复发的初始部位,而1974年后接受手术和辅助化疗的40例患者中只有18例(45%)仅以肺转移作为复发的初始部位。虽然早期组中没有患者以肺外转移作为复发的初始部位,但接受辅助化疗的40例患者中有11例(27.5%)以肺外转移作为复发性疾病的初始部位,11例患者同时发生肺和肺外转移。虽然不可能将转移模式的这种改变仅归因于辅助化疗,但很明显,在目前接受骨肉瘤治疗的患者中,非肺转移正变得越来越普遍。